Sareum - Specialists in Cancer Drug Discovery
Print the page Smaller text Larger text

 

First Patent Grant for Sareum’s TYK2 Kinase Inhibitor Programme
10 November, 2014

Notice of AGM
10 November, 2014

Final Results
14 October, 2014

Holding(s) in Company
13 October, 2014

Promising Step in Psoriasis Drug Development
01 October, 2014

RSS news feed News feed
requires RSS news reader

Sareum Holdings
Last Trading 0.45
Trade Time 16:27am
Change 0.00
Open 0.43
Day's Range 0.427 - 0.4745
Volume 1697819

 

Sareum's small molecule drug discovery expertise is building value by developing drug candidates, focused on cancer and autoimmune disease, for licencing to pharmaceutical and biotechnology companies

 

Providing protein structure-based research services to accelerate customers’ drug discovery programmes
Developing oncology drug candidates for licensing to pharmaceutical companies

 

Learn more about Sareum’s pipeline of targeted small molecule drug candidates

Annual Report & Accounts 2014 can be downloaded from our Information Page

                                                                                  Website last updated on: 11-November-2014

 

 


Requires RSS news reader

Requires MS Word

Requires Adobe Acrobat Reader


site map

cookie policy

email: info (at) sareum.co.uk tel: +44 (0) 1223 497700 fax: +44 (0) 1223 497701